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ABSTRACT 
 Human pluripotent stem cells (hPSCs), including embryonic and induced pluripotent 
stem cells (hESCs and hiPSCs) show unique cell cycle characteristics, such as a short doubling 
time due to an abbreviated G1 phase. Whether or not the core cell cycle machinery directly 
regulates the stemness and/or the differentiation potential of hPSCs remains to be determined. To 
date, several scenarios describing the atypical cell cycle of hPSCs have been suggested, and 
therefore there is still controversy over how cyclins, master regulators of the cell cycle, are 
expressed and regulated. Furthermore, the cell cycle profile and the expression pattern of major 
cyclins in hESCs-derived neuroprogenitors (NP) have not been studied yet. Therefore, herein we 
characterized the expression pattern of major cyclins in hPSCs and NP. We determined that all 
studied cyclins mRNA expression levels fluctuate along cell cycle. Particularly, after a thorough 
analysis of synchronized cell populations, we observed that cyclin E1 mRNA levels increased 
sharply in G1/S concomitantly with cyclin E1 protein accumulation in hPSCs and NP. 
Additionally, we demonstrated that cyclin E1 mRNA expression levels involves the activation of 
MEK/ERK pathway and the transcription factors c-Myc and E2Fs in hPSCs. Lastly, our results 
reveal that proteasome mediates the marked down-regulation (degradation) of cyclin E1 protein 
observed in G2/M by a mechanism that requires a functional CDK2 but not GSK3β activity. 
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 Human pluripotent stem cells (hPSCs), generated from embryo at the blastocyst stage 
(embryonic stem cells or hESCs) or from reprogrammed somatic cells (induced pluripotent stem 
cells or hiPSCs), are self-renewing cells that can potentially be a source for regenerative 
medicine as they can be differentiated into a wide range of specialized cells. Currently, they are 
being increasingly used as in vitro models for human development studies, disease modeling and 
drug discovery [1, 2]. 
 The ability of hPSCs to maintain their self-renewal and pluripotency is associated with 
their capacity to remain in a proliferative condition [3, 4]. To achieve this, hPSCs are endowed 
with an atypical cell cycle which lacks fully formed G1 and G2 gap phases and in which a high 
proportion of time (60%) is devoted to DNA replication (S phase). While there are exceptions, 
hPSCs generally have short generation times of 8-16 hours [5, 6, 7]. Importantly, when hESCs 
initiate a differentiation process, cells accumulate in the G1 phase and lengthen their cell cycle 
(more than 16 hours) [8]. A short G1 phase limits the time in which hPSCs can be influenced by 
external differentiation signals, as this phase represents the time with increased sensitivity to 
differentiation cues [9, 10]. Moreover, it has been demonstrated that inhibiting progression of the 
G1 phase commits hESCs differentiation [11, 12]. 
The transition from one cell cycle phase to another is governed by key regulators called 
cyclin-dependent kinases (CDKs), a family of serine/threonine protein kinases which are 
activated at specific points during cell cycle and whose actions are dependent on their 












stages of the cell cycle differ, whereas the CDK protein levels remain stable [14]. In particular, 
somatic cells cycle progression from G1 to S phases depends in part of the fine regulation of the 
activity of the complexes formed by the catalytic subunits CDK2, CDK4 and CDK6, whose 
expression levels remain constant, and the regulatory subunits, D-type (D1, D2 and D3) and E 
cyclins, whose expression levels oscillate during the cell cycle [15]. The activities of the 
cyclin/CDK complexes are counteracted by the action of small polypeptides, the CDK inhibitors 
(CKIs) [16, 17]. However, in murine embryonic stem cells (mESCs) most cyclins and CDKs are 
expressed throughout the cell cycle. High levels of CDKs activities in mESCs are due in part to 
the absence or low expression of CKIs, which in turn are linked to the high levels of cyclins that 
remain present during the cell cycle [18]. 
At present, to the best of our knowledge there is only a limited amount of information 
referred to cell cycle regulation in hPSCs and most of it relies on hESCs. Although, under certain 
circumstances, these cells exhibit a cell cycle similar to mESCs [18], differences in cell cycle 
control between hESCs and mESCs are evident, and have encouraged several groups to study the 
expression profiles of key cell cycle regulators in hESCs [19]. In particular, and in contrast to 
mESCs, most cell cycle regulators in hESCs exhibit a phase-specific expression [20]. However, 
there are discrepancies between results from different research groups regarding the abundance 
and periodic or constitutive expression of some cyclins during hESCs cell cycle [3, 5, 9, 20, 21, 
22, 23]. Besides, there is not much knowledge about how cyclins are expressed or regulated in 
hiPSCs [6]. 
In addition, studies related to the development of the central nervous system (CNS) were 
until recently limited by the lack of experimental models capable of accurately reproducing the 












of neuroprogenitors (NP) from hPSCs allowed us to count on very valuable tools for the study of 
the biological processes underlying CNS development. 
Throughout embryonic development cells must proliferate until reaching an appropriate 
number, and then they initiate differentiation with a concomitant change in cell cycle. The 
precise moment in which a cell changes the cell cycle pattern and initiates its differentiation is 
critical, since it directly impacts both the total number and the type of cell that is generated. To 
date, the way in which proliferation and differentiation processes are coordinated during the 
early stages of CNS development has not been fully elucidated. On this sense, little is still known 
about how cyclins are expressed or regulated in hPSCs-derived NP, and whether they show 
specific regulation or are regulated as in somatic cells or as in hPSCs. 
Taking these considerations into account, the present work was undertaken to evaluate the 
expression of cyclins in hESCs, hiPSCs and in hESC-derived neural progeny. Interestingly, we 
found that D-type cyclins are expressed in higher levels in NP and human foreskin fibroblasts 
(HF) than in hPSCs and that cyclins E1, A2 and B1 are highly expressed in hPSCs. Besides, we 
determined that all cyclins mRNAs were periodically expressed. In particular, cyclin E1 mRNA 
and protein expression levels peaked in G1/S in hPSCs and NP and its protein levels were down-
regulated in G2/M. Moreover, we observed that MEK/ERK1/2 signaling, c-Myc and E2Fs may 
be involved, at least in part, in the regulation of cyclin E1 mRNA expression levels in hPSCs. 
Finally, we demonstrated that proteasome-mediated degradation of cyclin E1 in G2/M in hPSCs 















Comparison of mRNAs and protein expression levels of cyclins in hPSCs, NP and HF 
 We first validated the pluripotent nature of hPSCs [WA09 (H9) hESCs and FN2.1 
hiPSCs] grown on Geltrex coated culture dishes with CM. H9 and FN2.1 cells exhibited robust 
expression of stem cells associated markers, such as nuclear located transcription factors 
Octamer 4 (Oct-4) and Nanog, and no expression of the mesenchymal associated marker 
Vimentin (Supplementary Figure 1a). No areas of lack of expression of stemness markers were 
detected. In contrast, HF did not express Oct-4 and Nanog but were positive for Vimentin 
(Supplementary Figure 1a). Moreover, tested cell lines also expressed significant high levels of 
stemness associated transcripts, quantified by RT-Real time PCR, such as oct-4 and nanog, 
compared to HF (Supplementary Figure 1b). Besides, hPSCs responded to an embryoid body 
(EB)-based differentiation protocol. In fact, on day 14 of the differentiation protocol we 
observed formation of neuroectoderm, endoderm and mesoderm (cardiac contractile regions), 
positively stained for Nestin, Alpha-fetoprotein (AFP) and cardiac Troponin T (cTnT), 
respectively (Supplementary Figure 1d). These results confirm the maintenance of hPSCs 
pluripotent characteristics under the experimental conditions used. Next, we determined that H9 
hESCs-derived NP expressed the neural progenitor marker Nestin and did not express Oct-4 and 
Nanog (Supplementary Figure 1c). These NP further differentiate into process-bearing neuronal-
like cells that stain positively for microtubule-associated protein MAP-2 and neuron-specific 
class III β-tubulin (TUJ-1) (Supplementary Figure 1e). 
 As previously mentioned hPSCs present an atypical cell cycle regulation which differs 
from the canonical one exhibited by somatic cells. hPSCs cell cycle is characterized mainly by 












sense, there are still controversies regarding the expression pattern of key cell cycle regulators 
like cyclins in human pluripotent cells. 
 Given the differences between the percentages of cells residing in each cell cycle phase at 
any given time, and because in somatic cells like HF cyclins are periodically expressed, herein 
we performed experiments with both asynchronously proliferating and pharmacologically 
arrested cells. 
 To accomplish this, we first arrested H9 hESCs, FN2.1 hiPSCs (both grown on Geltrex 
coated dishes with CM), hESCs-derived NP and HF cells in G1 and G2/M phases using two 
pharmacological inhibitors: PD0332991 (PD) to arrest cells in early G1 phase and Nocodazole 
(NOCO) to arrest cells in G2/M phase. To determine the drugs effect on the cell cycle we 
quantified DNA content by PI staining followed by flow cytometry analysis. As expected, we 
observed that asynchronously growing hESCs and hiPSCs contain a higher percentage of cells in 
the S phase (41.73±8.3% and 34.03±5.71, respectively) than NP and HF (13.6 ± 7.1% and 12.1 ± 
2.6%, respectively) (Figure 1a). The strong resemblance between the cell cycle profiles of NP 
and HF suggests that as hPSCs undergo lineage commitment, proliferation rates decreases and 
organization of the cell cycle changes by extending the length of G1. 
 Next, we analyzed the effect of PD and NOCO on the distribution of cells within the 
different cell cycle phases in hESCs, hiPSCs, NP and HF cells, which possess different cell cycle 
profiles. In all tested cell types, PD treatment led to a marked increase in the number of cells in 
the G1 phase and caused a decrease of cells in G2 phase. On the other hand, after NOCO 
exposure, most of the cells were in the G2/M phase (Figure 1a). 
 Once established the experimental conditions, we sought to accurately determine the 












results were not due to the existing differences between the percentages of cells residing in the 
different phases of the cell cycle in each cell type. To this end, we analyzed the mRNAs 
expression levels of the most relevant cyclins (A2, B1, D1, D2, D3 and E1) by RT-qPCR in PD- 
and NOCO-treated cell types (hESCs, hiPSCs, NP and HF). Next, we compared individual 
cyclin mRNA expression levels among cell types arrested either with PD or with NOCO and 
expressed the values relative to those of HF to have as reference a somatic cell type (Figure 1b, 
heat map). Importantly, we found that most cyclins mRNAs expression levels were higher in 
hPSCs arrested both in G1 and in G2/M than in HF. However, a remarkable exception to this 
was cyclin D1 whose expression levels were significantly much lower in hPSCs. In contrast, in 
NP we observed a cyclins mRNA expression profile which in general terms results intermediate 
between HF and the hESCs line (H9) from which they were derived. Nevertheless, it is worth 
noting that in the case of NP cyclin D1 mRNA expression levels were nearer to the ones 
displayed by HF in G1 arrested cells, and that cyclin E1 transcripts were expressed to a similar 
extent in NP and in H9, being much higher than those determined in HF (heat map on Figure 1b 
and Supplementary Figure 2). 
 We next studied if there was a correlation between cyclins mRNA and protein expression 
levels among the different cell types. To this end, we analyzed the protein expression levels of 
the most relevant cyclins A, B1, D1, D2 and E1 by Western blot both in asynchronously 
proliferating hESCs, hiPSCs, NP and HF and in PD-arrested cells (Figure 2a and b). Comparison 
of cyclins expression levels under each experimental condition (asynchronously growing or PD-
arrested) revealed that in both conditions cyclins E1, A and B1 showed a significantly higher 
expression in hPSCs (H9 and FN2.1) than in HF and NP. Again, protein expression levels of 












derived (Figure 2a and b). However, D-type cyclins protein products were, with the exception of 
cyclin D2 in asynchronous NP, significantly higher in HF and NP than in hPSCs as previously 
observed in the case of cyclin D1 mRNA (Figure 2 and 1b). Interestingly, NP presented a 
significantly higher cyclin D1 and D2 protein expression levels than HF in PD-arrested cells 
(Figure 2b). 
 
Changes in cyclins mRNA expression levels throughout hPSCs, NP and HF cell cycle 
progression 
 Next, in order to determine whether the aforementioned cyclins mRNAs (A2, B1, D1, 
D2, D3 and E1) are periodically or constitutively expressed throughout the different stages of the 
cell cycle, we analyzed and compared their expression levels by RT-qPCR in hESCs, hiPSCs, 
NP and HF asynchronously growing or arrested in G1 or G2/M phases owing to the presence of 
PD or NOCO, respectively (Figure 3). 
 In the case of hPSCs (hESCs and hiPSCs) we observed that the expression levels of 
cyclins A2 and B1 transcripts were lower in G1-arrested cells and similar (cyclin A2) or higher 
(cyclin B1) in G2/M-arrested cells when compared to asynchronously proliferating cells (Figure 
3). Thus, we determined that mRNA expression levels of cyclins A2 and B1 were significantly 
higher in G2/M than in G1 stage. On the other hand, a different behavior was observed in D-type 
cyclins (D1, D2 and D3) mRNAs expression levels, which in general were higher in G1-arrested 
cells than in G2/M-arrested counterparts. Interestingly, we found no significant differences in 
cyclin E1 mRNA expression levels among asynchronous or early G1 or G2/M-arrested cells. 
Besides, hESC-derived-NP (Figure 3) exhibited a similar temporal expression profile to that of 












expression in PD-arrested NP) and E1; not being the case for cyclin D1 mRNA expression levels 
which markedly diminished in G2/M. Finally, as expected we determined that cyclins mRNAs 
were periodically expressed in HF. 
 At this point of our investigation, experiments allowed us to conclude that even though 
the relative expression levels of the vast majority of cyclins mRNAs in pluripotent and 
progenitor cells significantly differ among cell types, they are periodically expressed except for 
cyclin E1 mRNA whose expression seems to be constitutive. 
 
Regulation of cyclin E1 mRNA expression levels throughout cell cycle progression in hPSCs 
cultured with a fully defined medium 
 We next studied if cyclin E1 mRNA regulation throughout hPSCs cell cycle relies on cell 
culture conditions. As iMEF-CM and Geltrex contain multiple components that are not 
completely defined, including Knockout Serum Replacement and factors released by MEFs, we 
decided to culture hPSCs with a fully defined medium like Essential 8 (E8) on Vitronectin 
coated dishes. First we determined under these experimental conditions, by immunofluorescence, 
RT-qPCR and flow cytometry, a robust expression of stem cells associated markers Oct-4 and 
Nanog in hPSCs (Supplementary figure 3a, b and c). Moreover, hPSCs grown on Vitronectin 
coated dishes with E8 medium were effectively arrested in G1 and G2/M with PD and NOCO, 
respectively (Supplementary Figure 3c). Importantly, differentiation of PD-arrested cells was not 
induced under this experimental condition according to pluripotency (oct-4 and nanog) and early 
differentiation (brachyury, alpha-fetoprotein and nestin) markers mRNA expression levels 
quantified by RT-qPCR (Supplementary figure 4a and b). Then, in order to determine whether 












cell cycle when hPSCs are grown and maintained in E8 medium, we analyzed its expression 
levels by RT-qPCR in hESCs and hiPSCs asynchronously growing or arrested in G1 or G2/M 
phases owing to the presence of PD or NOCO, respectively. Again, we found no significant 
differences in cyclin E1 mRNA expression levels among asynchronous or early G1 or G2/M-
arrested cells (Figure 4a). 
 
Cyclin E1 mRNA expression levels are regulated by MEK/ERK, c-Myc and E2Fs in hPSCs 
 Basic Fibroblastic Growth Factor (bFGF) is a key component of all hPSCs cell culture 
media, including E8, as it is essential for the maintenance of hPSC stemness, self-renewal, 
viability and proliferation [24, 25]. Interaction of bFGF with their signaling receptors causes the 
phosphorylation of specific tyrosine residues that mediate interaction with cytosolic adaptor 
proteins and activation of the Phosphoinositide 3-kinase (PI3K)/AKT and MEK/ERK1/2 
signaling cascades, among others. In particular, PI3K/AKT and MEK/ERK1/2 transduction 
pathways are known to be activated by bFGF in hPSCs and have been shown to be important in 
cell-cycle, survival, proliferation and pluripotency regulation of these cells [26, 27, 28]. In order 
to test whether PI3K/AKT and/or MEK/ERK1/2 might be involved in cyclin E1 mRNA 
regulation in hPSCs, we analyzed cyclin E1 mRNA levels by RT-qPCR in asynchronous hESCs 
(H9) and hiPSCs (FN2.1) maintained in E8 medium after pharmacological inhibition of AKT 
(GSK690693, 10µM) or MEK (U0126, 20µM) for 24 hours. We observed a significant decrease 
in cyclin E1 mRNA levels, in both H9 and FN2.1 cells, only when MEK/ERK signaling pathway 
was inhibited with U0126 (0.74±0.04 and 0.30±0.02 fold induction vs. Vehicle for H9 and 
FN2.1, respectively) (Figure 4b). Importantly, the efficacy of AKT inhibition by GSK690693 in 












 Besides, c-Myc transcription factor has been reported as an enhancer for reprogramming 
and also as having an important role in stemness regulation [29, 30, 31, 32]. Moreover, cyclin E1 
has been identified as a transcriptional target of c-Myc in pluripotent stem cells and other cell 
types [33, 34]. Therefore, we tested if pharmacological inhibition of c-Myc with 10058-F4 
(100µM for 24 hours) affects cyclin E1 mRNA expression levels. Indeed, a significant decrease 
in cyclin E1 mRNA levels, in both H9 and FN2.1 cells, was found upon c-Myc inhibition 
(0.77±0.02 and 0.28±0.03 fold induction vs. Vehicle for H9 and FN2.1, respectively) (Figure 
4b). 
 On other hand, as occurs in many other cell types, we wondered whether cyclin E1 
mRNA levels may be induced by E2F family of transcription factors, particularly E2F1, in 
hPSCs [35, 36]. Thus, in order to test if E2Fs are mediating cyclin E1 mRNA expression levels, 
we quantified cyclin E1 mRNA levels by RT-qPCR in asynchronous hESCs (H9) and hiPSCs 
(FN2.1) maintained in E8 medium after 7 days treatment with the pan-E2Fs inhibitor 
HLM006474 (40µM). Notably, under these experimental conditions, we found a significant 
decrease in cyclin E1 mRNA levels in both H9 and FN2.1 cells (0.62±0.05 and 0.64±0.04 fold 
induction vs. Vehicle for H9 and FN2.1, respectively) (Figure 4c). 
 Taken together, the above results suggest that MEK/ERK, c-Myc and E2Fs may modulate 
cyclin E1 mRNA expression levels in hPSCs. Importantly, hPSCs stemness was not affected 
upon pharmacological inhibitors treatment (GSK690693, U0126, 10058-F4 and HLM006474) as 
no significant change in stemness markers (oct-4 and nanog) mRNA expression levels 
(quantified by RT-qPCR) was observed (Supplementary figure 4c). Moreover, we confirmed that 












induced as judged by early differentiation (brachyury, alpha-fetoprotein and nestin) markers 
mRNA expression levels quantified by RT-qPCR (Supplementary Figure 4b). 
 
Cyclin E1 mRNA expression levels peak in G1/S boundary 
 It is well established that in somatic cells cyclin E1 expression increases through the G1 
phase of the cell cycle and peaks near the G1/S boundary. Taken this into account, and 
considering that PD causes cell cycle arrest in early G1 stage, we asked whether in our 
experiments we were omitting the time window in which cyclin E reaches its highest expression 
level. To find the answer, we use a different inhibitor to arrest cells in late G1 or G1/S boundary. 
Thus, we arrested H9 hESCs, FN2.1 hiPSCs (both grown on Vitronectin coated dishes with E8) 
and NP in G1/S boundary with Aphidicolin (Figure 5a). After establishing the optimal 
experimental conditions, we analyzed cyclin E1 mRNA expression levels by RT-qPCR in 
hESCs, hiPSCs and NP asynchronously growing or arrested in G1/S boundary owing to the 
presence of Aphidicolin. Notably, we observed a significant up-regulation in cyclin E1 mRNA 
expression levels in G1/S boundary-arrested cells (1.73±0.16; 1.72±0.20 and 3.05±0.34 fold 
induction vs. Vehicle for FN2.1, H9 and NP, respectively) (Figure 5b). Besides, differentiation 
of Aphidicolin-arrested (G1/S boundary) cells was not induced (Supplementary figure 4a and b). 
Importantly, using this experimental approach we determined that cyclin E1 mRNA is also 
periodically expressed along hPSCs and NP cell cycle. 
 













 In view of the previously described cyclin E1 mRNA regulation in hPSCs and NP, we 
wondered whether the corresponding protein levels also fluctuate throughout the cell cycle. To 
this end, cyclin E1 protein levels were quantified by Western blot in asynchronous, G1- (PD 
treatment) and G2/M- (NOCO treatment) arrested H9 hESCs, FN2.1 hiPSCs (both grown on 
Geltrex coated dishes with CM) and NP cells. As occurred with mRNA regulation (Figure 3), no 
significant changes in cyclin E1 protein expression levels were observed between asynchronous 
and PD-arrested cells. However, a significant reduction in the abundance of cyclin E1 protein 
was evident in G2/M-arrested cells with NOCO (0.36±0.09; 0.35±0.08 and 0.43±0.08 fold 
induction vs. Control for FN2.1, H9 and NP, respectively) (Figure 6a). 
 Again, in order to discard that cyclin E1 protein regulation throughout hPSCs cell cycle 
could depend on cell culture conditions, above experiments were repeated in H9 hESCs and 
FN2.1 hiPSCs grown on Vitronectin coated dishes with E8 medium. Surprisingly, under these 
experimental conditions, a slight but significant up-regulation of cyclin E1 protein expression 
levels was observed in PD-arrested cells (1.68±0.32 and 1.57±0.14 fold induction vs. Control for 
FN2.1 and H9, respectively) (Figure 6b). Once more, down-regulation of cyclin E1 protein levels 
was observed in NOCO treated cells (0.34±0.05 and 0.34±0.04 fold induction vs. Control for 
FN2.1 and H9, respectively) (Figure 6b). 
 Next, we arrested hPSCs (grown on Vitronectin with E8) and NP in G1/S boundary with 
Aphidicolin and quantified cyclin E1 protein expression levels by Western blot. Importantly, we 
observed a strong and significant up-regulation of cyclin E1 protein levels in all cases 
(9.31±0.24; 4.68±1.48 and 2.32±0.31 fold induction vs. Control for FN2.1, H9 and NP, 












 Finally, as cyclin E1 protein levels down-regulation in S-G2/M phases could be a result 
of a side effect of the inhibitor used to arrest the cells, we decided to repeat the experiments 
using a different pharmacological inhibitor. Therefore, we tested Vincristine to arrest hPSCs 
(grown on Vitronectin with E8) in G2/M. After determining that hPSCs were effectively arrested 
in G2/M upon exposure to Vincristine (250nM for 24 hours) (Supplementary Figure 3c), cyclin 
E1 protein expression levels were analyzed by Western blot. Importantly, a strong and 
significant down-regulation of cyclin E1 protein expression levels was observed (0.34±0.14 and 
0.44±0.15 fold induction vs. Control for FN2.1 and H9, respectively) (Figure 6c). 
 Taken together, the above results indicate that cyclin E1 protein expression levels are 
periodically regulated through hPSCs and NP cell cycle, being up-regulated (similar to cyclin E1 
mRNA) in G1/S boundary and down-regulated in G2/M. 
 
Regulation of cyclin E1 mRNA and protein expression levels throughout hPSCs cell cycle 
progression after Aphidicolin block and release 
 hPSCs (H9 hESCs and FN2.1 hiPSCs) grown on Vitronectin coated dishes with E8 
medium were synchronized in G1/S boundary with Aphidicolin (10μg/ml for 20 hours) and then 
released to enter the cell cycle. First, in order to demonstrate that cells were properly released 
from the blocking procedure, cell cycle progression was analyzed at every 4 hours after release 
to a total of 32 hours (Figure 7a). Next, cyclin E1 mRNA and protein expression levels were 
quantified by RT-qPCR or Western blot in asynchronous or at different time points after 
Aphidicolin removal. Particularly, cyclin E1 mRNA levels peaked at G1/S boundary and 
remained high until 16 hours after release, with an accompanying rise in the population of cells 












release, cyclin E1 expression levels peaked again. Finally, a similar behavior, although delayed 
in time, was observed with cyclin E1 protein abundance (Figure 7c). Taken together, the above 
results indicate that cyclin E1 mRNA and protein expression levels are undoubtedly periodically 
regulated through hPSCs cell cycle progression. Importantly, cyclins A2, B1, D1, D2 and D3 
mRNA expression levels also showed a periodic behavior after Aphidicolin block and release 
experiments (Supplementary Figure 5). 
 
Regulation of cyclin E1 protein levels in G2/M phase 
 Cyclin E1 drives the transition from G1 to S phase through the assembly of pre-
replication complexes and activation of CDK2, leading to the initiation of DNA synthesis. In 
somatic cells, cyclin E1 peaks in expression at G1/S phase of the cell cycle. This periodicity in 
expression results from regulation of both mRNA abundance and protein degradation. Upon S 
phase entry CDK2 phosphorylation of cyclin E1 primes it for phosphorylation. These 
phosphorylation events create short regions in cyclin E1 that allow its ubiquitin-dependent 
proteasomal degradation during S phase and G2/M [37]. 
 In order to test if the above mentioned mechanism is also operative in hPSCs and hESCs-
derived NP, cyclin E1 protein levels were quantified by Western blot in asynchronous and 
G2/M- (NOCO treatment) arrested H9 hESCs, FN2.1 hiPSCs (both grown on Vitronectin with 
E8) and NP cells in the presence or absence of the proteasome inhibitor MG-132. Importantly, 
by Western blot analysis we found that proteasome inhibition significantly reverted cyclin E1 
down-regulation observed in G2/M-arrested cells (Figure 8a). Moreover, we then studied if 
CDK2 inhibition was also able to prevent cyclin E1 degradation in G2/M. To do so, we used a 












for MG-132 and demonstrated that CDK2 activity mediates cyclin E1 protein product down-
regulation in G2/M-arrested hPSCs and NP (Figure 8b). 
 Finally, as it has been reported that GSK3β can also phosphorylate cyclin E1 and regulate 
its turnover [38], we analyzed cyclin E1 protein expression levels by Western blot in 
asynchronous, G1- (PD treatment) and G2/M- (NOCO treatment) arrested H9 hESCs, FN2.1 
hiPSCs (both grown on Vitronectin with E8) and NP cells in the presence or not of CHIR99021 
(specific GSK3β inhibitor). Interestingly, in this cellular context we found that GSK3β inhibition 
was not able to prevent cyclin E1 turnover in G2/M. Not only that, but in the presence of the 
GSK3β inhibitor we determined that cyclin E1 protein levels diminished even more in G2/M 
(Figure 8c). Importantly, the efficacy of GSK3β inhibition by CHIR99021 in hPSCs has been 
recently confirmed in our lab [28]. 
 Altogether, the above results suggest that cyclin E1 turnover in G2/M in both hPSCs and 
NP relies on CDK2-mediated ubiquitin-dependent proteasomal degradation. Again, hPSCs 
pluripotency was not affected upon NOCO, MG-132, CDK2 inhibitor II and CHIR99021 
treatments under the experimental conditions described according to pluripotency markers (oct-4 




 hPSCs have become an essential tool for the study of developmental processes in vitro 
and also in other areas of basic biology, holding great promise for use in regenerative medicine 
or drug discovery. Thus, what precedes their safe use in clinic is the precise understanding of the 












knowledge about stem cell biology suggests a mechanistic link between cell cycle and self-
renewal and pluripotency networks. In this regard, it has been reported that Oct-4, Nanog and 
Sox2, master regulators of pluripotency, have roles in controlling transition through the cell 
cycle directly regulating genes required for the G1 to S phase transition such as CDK6 and 
Cdc25A, and to accelerate G1 progression [39, 40, 41]. Likewise, the cell cycle machinery has 
been implicated in the regulation of the aforementioned networks including targets such as Oct-
4, Nanog and Sox2 [42]. For example, Brumbaugh and colleagues reported that ERK2 and 
CDK1/cyclin A2 differentially phosphorylate Nanog in vitro, raising the possibility that CDK1 
functions analogously to ERK2, perhaps to sustain Nanog during S/M phase; however, this was 
only speculative at that point [43]. 
To the best of our knowledge several scenarios describing the cell cycle of hPSCs have 
been proposed until present, but the precise functional and molecular characteristics of hPSCs 
division cycle remain unanswered. Therefore, the present study attempted to shed some light into 
the understanding of cell cycle regulation in two types of hPSCs, hESCs and hiPSCs, putting 
special emphasis in the levels and timing of expression of several cyclins, particularly cyclin E1. 
Another current challenge for researchers is the efficient generation of hPSCs-derived 
renewable NP, which can further differentiate into neurons, for their potential use in cell 
replacement therapies. For this reason, in this work we also analyzed the cell cycle profile and 
the expression pattern of major cyclins in hESCs-derived NP, subject of research that as far as 
we know has not been studied yet. 
Herein, we confirmed that in H9 hESCs and FN2.1 hiPSCs (Figure 3) D-type cyclins 
mRNAs are periodically expressed in hPSCs. Moreover, we determined that cyclin D2 is the 












that cyclin D1 mRNA and protein expression levels are significantly lower than the ones 
observed in HF. In line with this finding, Card and colleagues reported that the levels of cyclin 
D1 are attenuated by miR-302a in hESCs [41]. Additionally, in 2010 the aforementioned group 
reported that cyclin D2 is expressed predominantly in hESCs (WA09/H9) and that, upon lineage 
commitment, at the early stages of differentiation a change in the expression ratio of cyclin D2 to 
D1 occurs [21]. 
Furthermore, in the case of type A- and B-cyclins, early studies with mESCs have 
revealed that cyclins A2 and B1 proteins are constitutive expressed and more abundant in 
mESCs than in somatic MEFs [44]. Consistent with these findings, Becker et al. observed 
similarly robust expression of A- and B-type cyclins in hESCs, attributing these high levels to 
the increased proportion of hESCs residing, at any given time, in S, G2 and M phases [5]. 
Supporting these findings, Neganova et al. showed that in hESCs cyclins A2 and B1 levels 
fluctuate during the cell cycle [22]. In line with this evidence, we found that cyclin A2 and B1 
mRNAs are periodically expressed in both hESCs and hiPSCs and determined that their mRNAs 
and protein expression levels are higher in hPSCs than in somatic HF independently of their 
distinct cell cycle distribution. Interestingly, Liu et al observed that Akt activity fluctuates across 
the cell cycle, mirroring cyclin A expression. Moreover, Cyclin A2-deletion-induced elevation of 
cellular apoptosis in mouse embryonic stem cells, supporting the idea that cyclin A2 may govern 
cellular survival in vivo largely by promoting Akt activation [45]. Thus, whether the elevated 
expression levels of cyclin A2 we observed contribute to govern cell survival of hPSCs by 
regulating Akt activity awaits to be determined. 
Last but not least, reports about the way cyclin E1 is regulated through hPSCs cell cycle 












immunocytochemistry that 100% of proliferating hESCs are positive for cyclin E1 protein 
concluding that it is constitutively expressed in undifferentiated hESCs similarly to what occurs 
in mESCs [9]. On the same line, more recently Singh et al. observed that cyclin E1 expression 
lacks cell cycle periodicity at the transcript and protein levels in H9 hESCs [23]. Conversely, 
Abdelalim et al. reported that protein levels of cyclin E1 increase around the G1/S boundary in 
hESCs [3]. In this sense, in the present study we determined that cyclin E1 mRNA and its protein 
product levels oscillate throughout the cell cycle peaking at G1/S in both hESCs and hiPSCs. 
Additionally, we found that there is a turnover of cyclin E1 protein levels in G2/M in these cell 
types. This last result is supported by Neganova et al., who has previously observed that hESCs 
display lower levels of cyclin E1 protein in G2/M [22]. 
 Taken together our results are somehow consistent with earlier findings regarding D-type, 
A1 and B2 cyclins mRNA and protein expression levels (abundance and cell cycle-associated 
periodicity) in hESCs. Importantly, herein we found that a similar molecular setting is also 
present in hiPSCs, another type of pluripotent cells. Even though, we found that fluctuations of 
cyclins mRNA expression levels over time differed between embryonic and induced pluripotent 
stem cells. The differences observed in the temporal fluctuation of cyclins mRNA between H9 
and FN2.1 cell lines could be explained, at least in part, by a gene expression signature that 
defines hiPSCs state as unique from that of hESCs [46]. 
 Further, after a thorough study of cyclin E1 gene expression using different chemical 
agents for cell cycle synchronization and cell culture conditions, we determined that its mRNA 
and protein product expression levels fluctuate throughout the cell cycle in both hPSCs types. 
The discrepancy between the aforementioned reports, especially in what respects to cyclin E1 












hESCs/hiPSCs lines used in the experiments among the different groups, the time in culture 
(number of passages) [20], the use of different experimental protocols or cell culture media, the 
time window in which synchronized cells are sorted/processed/analyzed, the contribution of 
some differentiated cells or the sensitivity of Western blot assays or in antibodies quality [19]. 
Noteworthy, herein different pharmacological inhibitors were used and block and release 
experiments were performed to synchronize cells in order to encounter and do not miss the time 
window in which cyclin E1 reaches its highest expression level and also to confirm that changes 
observed are not result of side effects of the inhibitor used. Interestingly, block and release 
experiments showed that the fluctuation of cyclin E1 mRNA expression levels were not mirrored 
by its protein levels, which can be due to differences in their stability and in the transcriptional 
and translational regulatory mechanisms. 
On the other hand, defining in greater detail the mechanistic aspects that connect cell fate 
switches to the cell cycle machinery will be instrumental in developing novel methods to more 
effectively generate specific cell types. With this purpose, in this study we also investigated 
changes occurring in cell cycle and in the expression profile of cyclins in hESCs progeny at the 
initial stages of neural differentiation. We found that this immature differentiated progeny 
(Nestin+/CD133+) display a cell cycle profile that highly resembles that of somatic cells with a 
highly populated G1 phase. It is important to mention that NP expressed significantly higher 
levels of D-type cyclins (cyclin D1 and D2) than HF and hPSCs. On this sense, it has been 
reported that overexpression of cyclin D1 and cyclin E1 in mice shortens G1-phase, leading to 
down-regulation of neurogenesis and increased populations of apical and intermediate progenitor 
cells [47, 48, 49, 50, 51]. Moreover, it has been also shown that cyclin D2 is essential for the 












51]. Thus, it is conceivable that the expression levels of cyclin D2 and E1 displayed by hESC-
derived NP would be required to sustain proliferation at this stage of differentiation. Recently, 
Pauklin et al. reported that in late G1, cyclin D1 is induced and forms a complex with locus-
specific transcription factors to recruit transcriptional coactivators onto neuroectoderm genes and 
corepressors onto endoderm genes in stem cells [52]. Importantly, it has been shown that the 
activities of D-type cyclins also promote neuroectoderm formation during hiPSCs generation 
through up-regulating Pax6 [53]. Thus, we can speculate that D-type cyclins may also influence 
phenotype-associated gene expression in NP. 
Next, we deepen our study on cyclin E1 mRNA regulation in asynchronous hPSCs. It 
should be mentioned that cyclin E1/CDK2 is considered the main cyclin/CDK complex in 
mESCs. Importantly, decreasing CDK2 activity was found to lengthen G1 establishing a 
canonical cell cycle profile in mESCs cells, which was followed by differentiation [54]. 
Importantly, similar results were also shown for hESCs [9, 22]. Moreover, cyclin E1 plays a key 
role during plenipotent hESCs derivation and, potentially, during normal embryo development as 
well [55]. As high levels of CDK2 activity may result of the elevated expression levels of cyclin 
E1, we aimed to study which signaling pathways are involved in cyclin E1 mRNA regulation in 
hPSCs. Even though PI3K/AKT and MEK/ERK1/2 signaling cascades cooperate to maintain 
hPSCs stemness [26, 27], only MERK/ERK1/2 inhibition causes the loss of hESCs self-renewal 
capacity and proliferation rate [27]. On the other hand, PI3K/AKT signaling pathway has a 
predominant relevance in ensuring hPSCs survival [28]. Consistent with these findings, on this 
report we demonstrated that only MEK/ERK1/2, but not PI3K/AKT, signaling pathway regulates 












In what respect to the study of transcription factors that could regulate cyclin E1 mRNA 
expression levels, we focused our attention in c-Myc and the E2F family. In the case of c-Myc, it 
was already reported that this transcription factor may play a key role in regulating promoters 
and microRNAs associated with core pluripotency-associated genes. These findings implicate 
targets of the c-Myc network not only in playing a key role in controlling the efficiency of 
reprogramming, but also in maintaining stem cell pluripotency [29, 31, 32]. Moreover, there 
have been identified direct c-Myc targets like cyclins, including cyclin E1, and CDKs in mESCs, 
suggesting the role of c-Myc in cell cycle regulation of pluripotent stem cells [33]. Thus, 
occupancy of cell cycle regulatory genes promoters by c-Myc may play a role in the rapid cell 
division of both murine and hPSCs. Indeed, we found that cyclin E1 mRNA expression levels 
diminished upon c-Myc inhibition with 10058-F4 in hPSCs. Interestingly, activation of ERK1/2 
markedly enhances c-Myc protein stability as a result of direct phosphorylation of serine-62 [56], 
which means that MEK/ERK1/2 could be upstream of c-Myc in cyclin E1 mRNA regulation. 
Curiously, it has been also demonstrated that cyclin E1/CDK2 can also phosphorylate c-Myc at 
serine-62 [57], suggesting that there could be a complex regulatory positive feedback loop 
between c-Myc and cyclin E1/CDK2 in hPSCs. However, further experiments should be 
performed in order to confirm this hypothesis.  
On the other hand, it is well known that cell cycle regulation of cyclin E transcription is 
mediated by E2F binding sites present in its promoter. Moreover, cyclin E1 is able to stimulate 
its own transcription through a positive feedback mechanism involving E2F activation [35, 58]. 
Particularly, E2F1 was described as the main E2F transcription factor directly involved in cyclin 
E1 regulation [36]. Indeed, we used a pan-E2Fs inhibitor and observed that, in hPSCs, cyclin E1 












asynchronous hPSCs, MEK/ERK1/2 signaling pathway plus c-Myc and E2Fs transcription 
factors may be responsible, at least in part, of the high cyclin E1 mRNA expression levels 
observed in both H9 hESCs and FN2.1 hiPSCs. 
 Last but not least, we decided to gain insight about how cyclin E1 protein levels are 
regulated during S-G2/M phases, as we observed a G2/M-turnover of the protein in both hPSCs 
and NP. As previously mentioned, it has been demonstrated in somatic cells that upon mitogenic 
stimuli, cyclin E1 peaks in expression at G1/S phase (mRNA and protein) and then the protein is 
degraded in S-G2/M phases of the cell cycle. Importantly, we observed the same periodical 
behavior in hPSCs and NP. Cyclin E1 degradation is mediated through at least two distinct 
ubiquitin-proteasome pathways: one involving the BCR (BTB-Cul-3-Rbx1) ubiquitin ligase that 
targets monomeric cyclin E1 [59] and the other the F-box protein Fbw7 (SCFFbw7, Skp1-Cul1-
Rbx1-Fbw7) ubiquitin ligase complex [37]. In somatic quiescent cells, monomeric cyclin E1 is 
constitutively degraded through the BCR-mediated pathway, which does not require cyclin E1 
phosphorylation [60]. Contrary, in proliferative somatic cells, upon S phase entry CDK2 
phosphorylation of cyclin E1 primes it for phosphorylation by GSK-3β and other kinases [38]. 
These phosphorylation events create short regions in cyclin E1 that are recognized by the 
SCFFbw7 complex which mediates cyclin E1 ubiquitination and in consequence its rapid 
proteasomal degradation during S phase and G2/M [35, 37, 38, 61]. As these mechanisms were 
not yet studied in undifferentiated hPSCs and its differentiated NP progeny, we analyzed cyclin 
E1 turnover in G2/M upon proteasome and CDK2 inhibition. Importantly, we demonstrated that 
in these cellular contexts, cyclin E1 is proteasome-degraded by a mechanism that requires CDK2 
activity. Thus, as cyclin E1 phosphorylation by CDK2 seems to be required, cyclin E1 turnover 












it was reported that undifferentiated mouse hepatic progenitor cells do not require BCR and, 
instead, utilize the SCFFbw7 pathway to regulate cyclin E1 [35, 62]. Accordingly, the BCR or 
SCFFbw7-dependent ubiquitination pathways appear to modulate cyclin E1 protein expression 
levels in a cell type- and differentiation stage-specific manner, being the SCFFbw7-mediated 
pathway the predominant mechanism in highly proliferative pluripotent or progenitors cells. 
Besides, before being degraded by the SCFFbw7-mediated proteasome pathway, cyclin E1 must 
be phosphorylated within conserved motifs called Cdc4 phosphodegrons (CPDs) [63]. Cyclin E-
CDK2 auto-phosphorylates at T62, T380 and S384 residues present in the CPDs. GSK3β, among 
others, phosphorylates T380 as well [35]. While T380 phosphorylation is largely constitutive, 
S384 can only be auto-phosphorylated by CDK2 and is the critical switch that initiates cyclin E1 
degradation [63]. Moreover, as phosphorylation of cyclin E1 by GSK3β on T380 was reported to 
be pivotal for cyclin E1 turnover [38], we studied the effect of GSK3β inhibition with a specific 
pharmacological inhibitor (CHIR99021) and found not even a partial reversion in cyclin E1 
turnover. It is possible that, under our experimental conditions, GSK3β activity has not a 
dominant role over CDK2-mediated cyclin E1 stability due to the high levels of PI3K/AKT 
activity, present in hPSCs and NP (stimulated and sustained by bFGF and EGF, respectively), 




Cell lines, culture and differentiation 
 hESCs WA09 (H9) were purchased from WiCell Research Institute 












derived from human foreskin fibroblasts at our laboratory in accordance with relevant guidelines 
and regulations and has been fully validated [64]. hPSCs lines were maintained on an inactivated 
mouse embryonic fibroblast (iMEF) feeder layer in medium comprised of Dulbecco’s Modified 
Eagle’s Medium/Ham’s F12 (DMEM/F12, Gibco, 
http://www.thermofisher.com/order/catalog/product/11330032) supplemented with 20% 
Knockout Serum Replacement (KSR, Gibco, 
http://www.thermofisher.com/order/catalog/product/10828028), 2 mM non-essential amino acids 
(Gibco, http://www.thermofisher.com/order/catalog/product/11140050), 2 mM L-glutamine 
(Gibco, http://www.thermofisher.com/order/catalog/product/25030081), 100U/ml penicillin/100 
μg/ml streptomycin (Gibco, http://www.thermofisher.com/order/catalog/product/15140122), 
0.1mM β-mercaptoethanol (Gibco, 
http://www.thermofisher.com/order/catalog/product/21985023) and 4ng/ml of bFGF (Gibco, 
http://www.thermofisher.com/order/catalog/product/PHG0023). hPSCs were transferred with 
1mg/ml collagenase IV into feeder-free diluted (1/100) Geltrex (Gibco, 
http://www.thermofisher.com/order/catalog/product/A1413302) coated dishes in iMEF 
conditioned medium (CM). For conditioning medium, 3×106 inactivated MEFs were incubated 
for 24 hours with 25 ml of DMEM/F12 medium supplemented with 5% KSR and 2 ng/ml of 
bFGF (in addition to the other aforementioned supplements) and stored at -20°C. After thawing, 
fresh aliquots of KSR and bFGF were added to the medium to render a final concentration of 
20% and 8 ng/ml, respectively.  
 To induce differentiation, hPSCs grown on iMEFs as colonies were dispersed with 1 
mg/ml collagenase IV for 1 hour. Cells were then transferred to non-adherent Petri dishes 












http://www.thermofisher.com/order/catalog/product/10437028), 2 mM L-glutamine, 100U/ml 
penicillin/100 μg/ml streptomycin used as differentiation medium. Cells were incubated in 
suspension at 37°C and 5% CO2 for 7 days. During the incubation, the suspended hESC clumps 
aggregated to form three-dimensional non-adherent embryoid bodies (EBs), which were then 
plated onto 0.1% gelatin coated 24-well microplates and cultured for an additional 7 days. 7 
days. Normally, within 2-4 days after plating, tissue like-structures including contractile areas 
and neural rosettes were observed in the outgrowth of the EB. 
 For some experiments feeder-free cultures of hPSCs were maintained on Vitronectin (0.5 
µg/cm2) coated dishes (VTN-N, Gibco, 
http://www.thermofisher.com/order/catalog/product/A14700) in combination with fully defined 
Essential 8 medium (E8, Gibco, http://www.thermofisher.com/order/catalog/product/A1517001). 
Cultures were split every 3 to 4 days by means of PBS-EDTA (Versene, Gibco, 
http://www.thermofisher.com/order/catalog/product/15040066) passaging. Before experiments, 
hPSCs grown on Vitronectin and E8 were dissociated into single cells using Accutase 1x (Gibco, 
http://www.thermofisher.com/order/catalog/product/A1110501) for 7 minutes, plated onto 
Vitronectin coated dishes (with addition of 10µM Y-27632 ROCK inhibitor) (Abcam, 
http://www.abcam.com/y-27632-dihydrochloride-ab120129.html) and grown until confluence 
with E8. 
 HF were prepared as primary cultures from freshly obtained human foreskins as soon as 
possible after surgery. Written informed consent was obtained from patients according to 
guidelines established by the Ethics Committee of the Fundación para la Lucha contra las 
Enfermedades Neurológicas de la Infancia (FLENI). Briefly, after fat and loose fascia removal, 












scalpel. The cut tissue was subjected to an overnight digestion with dispase and then followed by 
careful removal of the epidermis. The remaining dermis was placed in high glucose DMEM 
(Gibco, http://www.thermofisher.com/order/catalog/product/12430047), 10% FBS (vol/vol) 
(Gibco, http://www.thermofisher.com/order/catalog/product/12484028), plated onto tissue 
culture plates and incubated in a 37°C, 5% CO2, 90% humidity incubator. Within 7–10 days 
outgrowths of fibroblasts appeared. The isolated fibroblasts were then expanded, frozen and 
stored as described elsewhere. 
 Neural progenitors (NP) were previously derived from H9 hESCs [65]. Briefly, EBs were 
generated by cutting H9 colonies into small pieces with a needle, detaching them from the feeder 
layer and culturing them in an ultralow adhesion culture dish in DMEM/F12 medium 
supplemented with 20% KSR, 2 mM non-essential amino acids, 2 mM L-glutamine, 100 U/ml 
penicillin/100 μg/ml streptomycin, 0.1 mM β-mercaptoethanol for 4 days. Medium was then 
replaced with Neural induction medium [DMEM/F12 medium supplemented with N-2 
supplement (Gibco, http://www.thermofisher.com/order/catalog/product/17502048), 2 mM non-
essential amino acids and 1 μg/ml heparin (Sigma-Aldrich, 
https://www.sigmaaldrich.com/catalog/product/sial/h4784?lang=es&region=AR)]. To induce 
neural rosette formation, 6-day-old EB were plated on 20 μg/ml laminin-coated (Sigma, 
https://www.sigmaaldrich.com/catalog/product/sigma/l2020?lang=es&region=AR) dishes and 
cultured in Neural induction medium for 15 days. During the culture of EB on the laminin-coated 
surfaces, neural rosettes were observed and manually removed from the surrounding flat cells. 
Next, the rosettes were dissected into small pieces using a sterile pulled glass pipette under a 
stereomicroscope and plated on laminin-coated dishes and were cultured in a Neural proliferation 












http://www.thermofisher.com/order/catalog/product/21103049) supplemented with B-27 (Gibco, 
http://www.thermofisher.com/order/catalog/product/17504044), N-2, 2 mM L-glutamine, 2 mM 
non-essential amino acids, 100U/ml penicillin/streptomycin, 20 ng/ml bFGF, 20 ng/ml epidermal 
growth factor (EGF, Gibco, http://www.thermofisher.com/order/catalog/product/PHG0313), 
20μg/ml bovine pancreas insulin (Sigma, 
https://www.sigmaaldrich.com/catalog/product/sigma/i0516?lang=es&region=AR) and 75 μg/ml 
low-endotoxin bovine serum albumin (Sigma, 
https://www.sigmaaldrich.com/catalog/product/sigma/a8806?lang=es&region=AR). After the 
initial differentiation lasting 21 days, NP were dissociated using Accutase 1x for 5 min, 
centrifuged at 300 x g for 5 min, resuspended with Neural proliferation medium and plated on 
Geltrex coated dishes for further expansion and cryopreservation. 
 For neuronal differentiation, NP were suspended in Neurobasal medium supplemented 
with B-27, N-2, 2 mM L-glutamine, 2mM non-essential amino acids, 50 U/ml 
penicillin/streptomycin (all from Invitrogen, CA, USA), 20μg/ml bovine pancreas insulin and 75 
μg/ml low endotoxin bovine serum albumin (Sigma, MO, USA) as floating aggregates for three 
days. Then medium was replaced by Neural induction medium (DMEM/F12 medium 
supplemented with N-2, 2 mM non-essential amino acids and 1 μg/ml heparin) and cellular 
aggregates were expanded for 10 days. Medium was changed every 2 days. After neural 
expansion, the aggregates (neurospheres) were allowed to attach onto 10 μg/ml laminin-coated 
plates in Neural differentiation medium (Neurobasal medium supplemented with B-27, N-2, 10 
ng/ml BDNF (Gibco, http://www.thermofisher.com/order/catalog/product/PHC7074), 10 ng/ml 
GDNF (Gibco, http://www.thermofisher.com/order/catalog/product/PHC7041), 200 μg/ml 












https://www.sigmaaldrich.com/catalog/product/sigma/a4544?lang=es&region=AR), 0.1 μM 
cAMP (Sigma, 
https://www.sigmaaldrich.com/catalog/product/sigma/a9501?lang=es&region=AR) and 20 μg/ml 
laminin for 10 days. Medium was changed every 2 days. 
 All cell lines were free of Mycoplasma sp. infection, which was tested as previously 
described [66]. 
 
Immunostaining and fluorescence microscopy 
 hPSCs and its differentiated progeny, hESCs-derived NP and its neuronal differentiated 
progeny and HF were analyzed for in situ immunofluorescence. Briefly, cells were rinsed with 
ice-cold PBS and fixed in PBSA (PBS with 0.1% bovine serum albumin) with 4% formaldehyde 
for 45 min. After two washes with PBS, cells were permeabilized with 0.1% Triton X-100 in 
PBSA with 10% normal goat serum for 30 min, washed twice and stained with the corresponding 
primary antibodies. Fluorescent secondary antibodies were used to localize the antigen/primary 
antibody complexes. The cells were counterstained with DAPI and examined under a Nikon 
Eclipse TE2000-S inverted microscope equipped with a 20X E-Plan objective and a super high-
pressure mercury lamp. The images were acquired with a Nikon DXN1200F digital camera, 
which was controlled by the EclipseNet software (version 1.20.0 build 61). For information 
about antibodies used please see Supplementary methods (Table 3). 
 
RNA isolation and RT-qPCR 
 Total RNA was extracted using TRIzol reagent (Invitrogen, 












instructions. cDNA was synthesized using MMLV reverse transcriptase (Promega, 
https://www.promega.com/products/pcr/rt-pcr/m-mlv-reverse-transcriptase/?catNum=M1705)  
from 500 ng of total RNA. For real-time PCR studies, cDNA samples were diluted 5-fold and 
PCR amplification and analysis were performed with StepOnePlus Real Time PCR System 
(Applied Biosystems, http://www.thermofisher.com/order/catalog/product/4376600). The 
SYBR® GreenERTM qPCR SuperMix UDG (Invitrogen, 
http://www.thermofisher.com/order/catalog/product/11762100) was used for all reactions, 
following manufacturer’s instructions. For information about primers sequences please refer to 
Supplementary methods (Table 1). 
 
Synchronization experiments 
 To arrest cell cycle the following inhibitors were used: Nocodazole (a microtubule 
polymerization inhibitor) (Sigma, 
https://www.sigmaaldrich.com/catalog/product/sigma/m1404?lang=es&region=AR) and 
Vincristine (a mitotic spindle formation inhibitor)  (Sigma, 
https://www.sigmaaldrich.com/catalog/product/sigma/v8879?lang=es&region=AR), to arrest  at  
G2/M phase; PD0332991 (a specific inhibitor of CDK4/6)  (Sigma, 
https://www.sigmaaldrich.com/catalog/product/sigma/pz0199?lang=es&region=AR) and 
Aphidicolin (a specific inhibitor of DNA polymerase α, which is responsible for DNA 
replication) (Sigma, 
https://www.sigmaaldrich.com/catalog/product/sigma/a0781?lang=es&region=AR), to arrest at 
early G1 phase and G1/S phase boundary, respectively. Inhibitors were dissolved in DMSO 












(Nocodazole, Aphidicolin and Vincristine) or room temperature (PD0332991) protected from 
light. Inhibitors were added to cell cultures such that the final DMSO concentrations were not 
higher than 0.10% (v/v). 
 
Inhibitors 





HLM006474 (Tocris, https://www.tocris.com/products/hlm-006474_5283), CHIR99021 (Tocris, 
https://www.tocris.com/products/chir-99021_4423), MG-132 (Calbiochem, 
http://www.merckmillipore.com/AR/es/product/MG-132-CAS-133407-82-6-
Calbiochem,EMD_BIO-474790) and CDK2 inhibitor II (Santa Cruz Biotechnology, 
https://www.scbt.com/scbt/product/cdk2-inhibitor-ii-222035-13-4) reagents were used as 
AKT1/2, MEK1/2, c-Myc, E2Fs, GSK3β, proteasome and CDK2 inhibitors, respectively. 
Inhibitors were dissolved in DMSO and stored at -20 °C (GSK690693, HLM006474, MG-132 
and CDK2 inhibitor II) or 4 °C (U0126, 10058-F4) protected from light. Inhibitors were added to 
cell cultures such that the final DMSO concentrations were not higher than 0.10% (v/v). 
 
Flow cytometric analysis of cell cycle arrest by Propidium Iodide (PI) DNA staining 
 After inhibitors incubation, single-cell suspensions were obtained with Accutase 1x 












hydrated with PBS 3% FBS, left 40 minutes at 4 °C, then incubated 30 minutes at 37 °C with 
RNAse A (100 µg/ml) (Invitrogen, 
http://www.thermofisher.com/order/catalog/product/12091021), and then with Propidium Iodide 
(PI) (40 µg/ml) (Sigma-Aldrich, 
https://www.sigmaaldrich.com/catalog/product/sial/81845?lang=es&region=AR) for 5 minutes. 
Cells were immediately analyzed by flow cytometry. Data was acquired on a BD Accuri C6 flow 
cytometer (BD Biosciences, https://www.bdbiosciences.com/instruments/accuri/). The 
percentage of cells in each cell cycle phase was calculated by the FlowJo v10.0.7’s univariate 
platform (https://www.flowjo.com/solutions/flowjo/downloads) which assumes Gaussian 
distributions of the 2N and 4N (formerly G0/G1 and G2/M, respectively) populations, then uses 
a subtractive function to reveal the S-phase population. The cells within one standard deviation 
of the 2N and 4N medians are subtracted from the data, and the remaining cells (S-phase) are fit 
with a polynomial function that is convoluted with the Gaussian distributions of the 2N and 4N 
populations to form the complete model. 
 
Flow cytometric analysis of Oct-4 stemness marker 
 hPSCs grown on Vitronectin coated dishes with E8 medium were disassociated into 
single cells by treatment with Accutase and centrifuged at 1000 rpm for 5 min. After addition of 
4% formaldehyde and fixation at room temperature for 30 min, cells were washed three times 
with PBS/Albumin 0,1% and then permeabilized (in a solution containing 1% BSA, 10% normal 
goat serum and 0.1% Triton X-100) at room temperature for 45 min. Then, cells were incubated 
for 2h with a primary antibody targeting Oct-4 (1:50 in a solution containing 1% BSA, 10% 












for 45 min. with Alexa Fluor 488-conjugated goat anti-mouse IgG secondary antibody (1:400) 
under dark conditions at room temperature. After centrifugation, cells were washed three times 
with PBS/Albumin 0,1%, resuspended in this solution and analyzed on a BD Accuri C6 flow 
cytometer. Normal mouse IgG was used as isotype control. 
 
Protein analysis 
 Total proteins were extracted from hPSCs and NP in ice-cold RIPA protein extraction 
buffer (Sigma, 
https://www.sigmaaldrich.com/catalog/product/sigma/r0278?lang=es&region=AR) 
supplemented with protease inhibitors (Protease inhibitor cocktail set I, Calbiochem, 
http://www.merckmillipore.com/AR/es/product/Protease-Inhibitor-Cocktail-Set-I-
Calbiochem,EMD_BIO-539131). Protein concentration was determined using Bicinchoninic 
Acid Protein Assay (Pierce, http://www.thermofisher.com/order/catalog/product/23225). Equal 
amounts of protein were run on 12% SDS-polyacrylamide gel electrophoresis and transferred to 
PVDF (Millipore, http://www.merckmillipore.com/AR/es/product/Immobilon-P-PVDF-
Membrane,MM_NF-IPVH304F0) membranes. Blots were blocked 1 hour at room temperature in 
TBS (20 mM Tris-HCl, pH 7.5, 500 mM NaCl) containing low-fat powdered milk (5%) and 
Tween 20 (0.1%). Incubations with primary antibodies were performed overnight at 4 °C in 
blocking buffer (3% skim milk, 0.1% Tween, in Tris-buffered saline). Membranes were then 
incubated with the corresponding counter-antibody and the proteins revealed by enhanced 
chemiluminescence detection (SuperSignal West Femto System, Thermo Scientific, 
http://www.thermofisher.com/order/catalog/product/34095). For information about antibodies 












performed with ImageJ 1.34s software (Wayne Rasband, National Institutes of Health, 
https://imagej.nih.gov/ij/) for chemiluminescence detection. Representative whole membrane 
blots showing the specificity of cyclins (D1, D2, E1, A and B1) antibodies are shown in 
Supplementary Figure 6. 
 
Statistical analysis 
 All results are expressed as mean + SEM. Two-tailed Student’s t-test were used to detect 
significant differences (p<0.05) among treatments as indicated. Statistical analysis was made 
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Figure 1. Comparison of mRNAs expression levels for cyclins in synchronous hPSCs, NP and 
HF. (a) Human fibroblasts (HF), hiPSCs (FN2.1), hESCs (H9) and NP derived from H9 cells 
were arrested in G1 with PD0332991 (PD) (48h 1μM for HF, 30h 5μM for hPSC and 24h 1μM 
for NP) and in G2/M with Nocodazole (NOCO) (72h 200ng/ml for HF, 24h 100ng/ml for hPSC 
and 54h 200ng/ml for NP). Cell cycle profile of asynchronous and pharmacologically arrested 
cells was analyzed after cells were fixed with cold 70% ethanol. DNA content was measured 
with propidium iodide (PI) and its fluorescence was determined with a flow cytometer. A 
representative DNA content frequency histogram plot is shown for each condition. The 
percentage of cells in each cell cycle phase was calculated by the FlowJo v10.0.7’s univariate 
platform. N=3. (b) Heat maps representing mRNA expression levels quantified by RT-qPCR of 
cyclins D1, D2, D3, E1, A2 and B1 in HF, FN2.1, H9 and NP cells arrested with in G1 with PD 
or in G2/M with NOCO following the same experimental conditions described in (a). rpl7 
expression was used as normalizer. The mRNA fold induction is relative to HF control cells 
(synchronous cells) arbitrarily set as 1. N=5. Results are shown as a heat map generated with the 
software CIMminer. 
 
Figure 2. Comparison of protein expression levels for cyclins in asynchronously proliferating 
and G1 arrested hPSCs, NP and HF cells. Expression levels of cyclins D1, D2, E1, A and B1 
were analyzed by Western blot in HF, FN2.1 (hiPSCs), H9 (hESCs) and NP cells 
asynchronously growing (Asynchronous) (a) or arrested in G1 with PD0332991 (PD) (1µΜ for 
48h for HF, 5μM for 30h for hPSCs and 1μM for 24h for NP) (b). Actin was used as loading 












experiments are shown. (*) p<0.05, (**) p<0.01 and (***) p<0.001 vs. HF; (&) p<0.05, (&&) 
p<0.01 and (&&&) p<0.001 vs. H9. 
 
Figure 3. Changes in cyclins mRNA expression levels throughout hPSCs, NP and HF cell 
cycle progression. Analysis of mRNA expression level changes of cyclins A2, B1, D1, D2, D3 
and E1 quantified by RT-qPCR in asynchronous or synchronous G1 (PD arrested) or G2/M 
(NOCO arrested) HF, FN2.1, H9 and NP cells. rpl7 expression was used as normalizer. Graphs 
show mean + SEM mRNA fold induction relative to asynchronous control cells, arbitrarily set as 
1. N=5, (*) p<0.05, (**) p<0.01 and (***) p<0.001 vs. Control (asynchronous cells). 
 
Figure 4. Changes in cyclin E1 mRNA expression level throughout hPSCs (grown in defined 
medium) cell cycle progression and in asynchronous cells after PI3K/AKT, MEK/ERK, c-Myc 
and E2Fs inhibition. Analysis of mRNA expression levels of cyclin E1 quantified by RT-qPCR 
in: (a) asynchronous or synchronous G1 (PD arrested, 5μM for 30h) or G2/M (NOCO arrested, 
100ng/ml for 24h) FN2.1 and H9 hPSCs grown and maintained in fully defined conditions 
(Vitronectin coated dishes and E8 medium); (b) asynchronous FN2.1 and H9 hPSCs grown with 
E8 medium at 24 hours post AKT, MEK1/2 and c-Myc inhibition with GSK690693 (10µM), 
U0126 (20µM) and 10058-F4 (100µM), respectively; and (c) asynchronous FN2.1 and H9 
hPSCs grown with E8 medium during 7 days in the presence of the pan-E2Fs inhibitor 
HLM006474 (40µM). rpl7 expression was used as normalizer in all cases. Graphs show mean + 
SEM mRNA fold induction relative to asynchronous or Vehicle (DMSO treated) control cells 
(arbitrarily set as 1) of at least three independent experiments. (*) p<0.05, (**) p<0.01 and (***) 













Figure 5. Regulation of cyclin E1 mRNA expression levels in G1/S boundary. (a) hiPSCs 
(FN2.1), hESCs (H9) (both grown with E8 medium) and NP derived from H9 cells were arrested 
in G1/S boundary with Aphidicolin (10μg/ml for 20h hPSCs and 10μg/ml for 48h for NP). Cell 
cycle profile of asynchronous and pharmacologically arrested cells was analyzed after cells were 
fixed with cold 70% ethanol. DNA content was measured with propidium iodide (PI) and its 
fluorescence was determined with a flow cytometer. A representative DNA content frequency 
histogram plot is shown for each condition. The percentage of cells in each cell cycle phase was 
calculated by the FlowJo v10.0.7’s univariate platform. N=3. (b) Analysis of mRNA expression 
levels of cyclin E1 quantified by RT-qPCR in asynchronous or synchronous G1/S (Aphidicolin) 
FN2.1 and H9 hPSCs (both grown and maintained in Vitronectin coated dishes and E8 medium) 
and NP. rpl7 expression was used as normalizer. Graphs show mean + SEM mRNA fold 
induction relative to asynchronous control cells (arbitrarily set as 1) of at least three independent 
experiments. (*) p<0.05 and (***) p<0.001 vs. Control (asynchronous cells). 
 
Figure 6. Changes in cyclin E1 protein expression levels throughout hPSCs and NP cell cycle 
progression. Analysis of cyclin E1 protein expression levels quantified by Western blot in 
asynchronous (Control) or synchronous G1 (PD arrested, 5μM for 30h for hPSCs and 1μM for 
24h for NP) (a, b), G1/S boundary [Aphidicolin (Aph.) arrested, 10μg/ml for 20h for hPSCs and 
10μg/ml for 48h for NP] (c) or G2/M [NOCO arrested, 100ng/ml for 24h for hPSCs and 
200ng/ml for 54h for NP (a, b); Vincristine (Vcr.) 250nM for 24h for hPSCs (c)] FN2.1 and H9 
hPSCs [grown in Geltrex coated dishes with CM (a) or in Vitronectin coated dishes with E8 (b, 












Control (asynchronous cells, arbitrary set as 1) and representative blots of three independent 
experiments are shown. (*) p<0.05, (**) p<0.01, (***) p<0.001 vs. Control. 
 
Figure 7. Changes in cyclin E1 mRNA and protein expression levels throughout hPSCs cell 
cycle progression after Aphidicolin block and release. H9 hESCs and FN2.1 hiPSCs grown in 
Vitronectin coated dishes with E8 medium were synchronized at G1/S boundary by Aphidicolin 
(Aph.) block (10μg/ml for 20h) and released to enter the cell cycle, and then: (a) Cells were 
harvested at the indicated time points after release and fixed with cold 70% ethanol. DNA 
content was measured with propidium iodide (PI) and its fluorescence was determined with a 
flow cytometer to determine DNA content. A representative DNA content frequency histogram 
plot is shown for each time point. N=3. Control: asynchronous cells. h: hours. (b) cyclin E1 
mRNA expression levels were quantified by RT-qPCR in asynchronous or at different time 
points after Aphidicolin (Aph.) removal. rpl7 expression was used as normalizer. Graphs show 
mean + SEM mRNA fold induction relative to asynchronous control cells (arbitrarily set as 1) of 
at least three independent experiments. h: hours. (*) p<0.05 and (**) p<0.01 vs. Control 
(asynchronous cells). (c) cyclin E1 protein expression levels were quantified by Western blot in 
asynchronous or at different time points after Aphidicolin (Aph.) removal. Actin was used as 
loading control. Mean + SEM fold induction relative to Control (asynchronous cells, arbitrary set 
as 1) and representative blots of three independent experiments are shown. h: hours. (*) p<0.05, 
(**) p<0.01, (***) p<0.001 vs. Control. 
 
Figure 8. Regulation of cyclin E1 protein expression levels in G2/M phase. Analysis of cyclin 












synchronous G2/M (NOCO arrested, 100ng/ml for 24h for hPSCs and 200ng/ml for 54h for NP) 
(a, b and c) or G1 (PD arrested, 5μM for 30h for hPSCs and 1μM for 24h for NP) (c) FN2.1 and 
H9 hPSCs (grown in Vitronectin coated dishes with E8) and NP cells treated or not with 
proteasome inhibitor MG-132 (MG132, 62.5nM for 24h for hPSCs and 62.5nM for 54h for NP) 
(a), CDK2 inhibitor II (CDK2i, 5µM for 24h for hPSCs and 5µM for 54h for NP) (b) and 
GSK3β inhibitor CHIR99021 (CHIR, 10µM for 24h) (c). Actin was used as loading control. 
Mean + SEM fold induction relative to Control (asynchronous cells, arbitrary set as 1) and 
representative blots of at least three independent experiments are shown. (*) p<0.05, (**) 
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Antibodies and primers used: 
 Primer sequence ( 5' → 3') 
Name Forward Reverse 
RPL7 AATGGCGAGGATGGCAAG TGACGAAGGCGAAGAAGC 
cyclin A2 CCTGCAAACTGCAAAGTTGA AAAGGCAGCTCCAGCAATAA 
cyclin B1 CAAGCCCAATGGAAACATCT GGATCAGCTCCATCTTCTGC 
cyclin D1 GATCAAGTGTGACCCGGACT TCCTCCTCCTCTTCCTCCTC 
cyclin D2 TTGTTCCCGAGCGATAGATG ACCAGAAGCGAAGAGTAACC 
cyclin D3 GTGGCCACTAAGCAGAGGAG TTTGTGAAGGGGGAACAGAC 
cyclin E1 AGGGGACTTAAACGCCACTT AGGGGACTTAAACGCCATT 
Oct-4 CTGGGTTGATCCTCGGACCT CACAGAACTCATACGGCGGG 
Nanog AAAGAATCTTCACCTATGCC GAAGGAAGAGGAGAGACAGT 
Brachyury TCCCAGGTGGCTTACAGATGA GGTGTGCCAAAGTTGCCAAT 
AFP TGCTGGATTGTCTGCAGGATG ACGTTCCAGCGTGGTCAGTTT 
Nestin CAGCTGGCGCACCTCAAGATG AGGGAAGTTGGGCTCAGGACTGG
Table 1. Primers used for RT-qPCR experiments. 
Antibody Specie Brand N° Catalogue Dilution 
α-cyclin E1 Monoclonal-Mouse BD Biosciences BDB-551159 1/1000 
α-cyclin D1 Monoclonal-Mouse Santa Cruz Sc-8396 1/1000 
α-cyclin D2 Monoclonal-Mouse Santa Cruz Sc-376676 1/1000 
α-cyclin A Monoclonal-Mouse Santa Cruz Sc-271682 1/1000 












α-Actin Polyclonal-Goat Santa Cruz Sc-1616 1/1000 
Table 2. List of primary antibodies used for Western Blot analysis 
Antibody Specie Brand N° Catalogue Dilution 
α-Nanog Monoclonal-Rabbit Cell Signaling D73G4 1/400 
α-Oct-4 Monoclonal-Mouse Santa Cruz Sc-5279 1/200 
α-Vimentin Monoclonal-Mouse Dako M0725 1/200 
α-Nestin Polyclonal-Rabbit Chemicon AB5922 1/400 
α-cTnT Monoclonal-Mouse Santa Cruz Sc-20025 1/200 
α-AFP Monoclonal-Mouse Santa Cruz Sc-166325 1/200 
α-MAP2 Monoclonal-Mouse Sigma M1406 1/400 
α-TUJ-1 Monoclonal-Mouse Covance MMS-435P 1/400 




















Supplementary Figure 1. hPSCs, NP and HF characterization: expression of stem cell and 
lineage-specific markers. (a) Representative micrographs of immunofluorescent staining of 
WA09 (H9) hESCs, FN2.1 hiPSCs and HF cultured as described in Methods and then fixed and 
stained with primary antibodies recognizing Octamer 4 (Oct-4) and Nanog stem cell markers and 
Vimentin mesenchymal marker. The scale bars represent 100 µm. (b) RT-qPCR analyses of stem 












hiPSCs, HF and H9-derived NP. rpl7 expression was used as normalizer. Graph shows mRNA 
fold induction relative to HF. The mean + SEM from three independent experiments are shown. 
(*) p<0.05, (**) p<0.01, (***) p<0.001 vs. HF. (&&) p<0.01 vs. H9. (c) Representative 
micrographs of immunofluorescent staining of H9-derived NP fixed and stained with primary 
antibodies recognizing Oct-4 and Nanog stem cell markers and Nestin neural progenitor cell 
marker. The scale bars represent 100 µm. (d) H9 and FN2.1 cells were differentiated using an 
embryoid body- (EB) based protocol, grown on gelatin coated plates from day 7 to 14 of 
differentiation and then ectoderm (neural rosettes), cardiac mesoderm (contractile EB) and 
endoderm structures were stained with primary antibodies that recognize Nestin (ectoderm), 
Cardiac troponin T (cTnT) (cardiac mesoderm) and Alpha-feto protein (AFP) (endoderm) 
markers. Figure shows representative images. The scale bars represent 100 µm. (e) 
Representative images of neuronal-like cells differentiated from H9-derived NP stained with 






















Supplementary Figure 2. Comparison of mRNAs expression levels for cyclins in synchronous 
hPSCs, NP and HF. mRNA expression levels quantified by RT-qPCR of cyclins D1, D2, D3, 
E1, A2 and B1 in HF, hiPSCs (FN2.1), hESCs (H9) and NP cells arrested in G1 with PD0332991 
(PD) or in G2/M with Nocodazole (NOCO) under the same experimental conditions described in 
Figure 1A. rpl7 expression was used as normalizer. Graph shows mean + SEM mRNA fold 
induction relative to HF control cells arbitrarily set as 1 from five independent experiments. * 







Cell cycle profile of asynchronous and pharmacologically arrested hPSCs cultured with a 















Supplementary Figure 3. Cell cycle profile of asynchronous and pharmacologically arrested 
hPSCs cultured with E8 medium. Validation of stemness phenotype (a) Representative 
micrographs of immunofluorescent staining of H9 hESCs and FN2.1 hiPSCs cultured in fully 
defined conditions (Vitronectin coated dishes and E8 medium) and then fixed and stained with 
primary antibodies recognizing Oct-4 and Nanog stem cell markers. The scale bars represent 100 












on undifferentiated H9 hESCs and FN2.1 hiPSCs cultured in Vitronectin coated dishes and E8 
medium. rpl7 expression was used as normalizer. Graph shows mRNA fold induction relative to 
HF. The mean + SEM from three independent experiments are shown. (*) p<0.05, (**) p<0.01, 
(***) p<0.001 vs. HF. (c) Indirect intracellular flow cytometry analysis of fixed and 
permeabilized H9 hESCs and FN2.1 hiPSCs cultured in Vitronectin coated dishes and E8 
medium stained with Oct-4, followed by Alexa Fluor 488-conjugated goat anti-mouse IgG (blue 
line histogram). Red line histogram represents isotype control. N=3. (d) hiPSCs (FN2.1) and 
hESCs (H9) grown and maintained in fully defined conditions (Vitronectin coated dishes and E8 
medium) were arrested in G1 with PD0332991 (PD) (5μM for 30h) and in G2/M with 
Nocodazole (100ng/ml for 24h) or with Vincristine (250nM for 24h). Cell cycle profile of 
asynchronous and pharmacologically arrested cells was analyzed after cells were fixed with cold 
70% ethanol. DNA content was measured with propidium iodide (PI) and its fluorescence was 
determined with a flow cytometer. A representative DNA content frequency histogram plot is 
shown for each condition. The percentage of cells in each cell cycle phase was calculated by the 
FlowJo v10.0.7’s univariate platform. N=3. 
 

























Supplementary Figure 4. Differentiation status of pharmacologically G1- and G1/S-arrested 
hPSCs after treatment. (a) and (b) hESCs (H9) and hiPSCs (FN2.1) grown and maintained in 
fully defined conditions (Vitronectin coated dishes and E8 medium) were arrested in G1 with 
PD0332991 (PD) (5μM for 30h) and in G1/S with Aphidicolin (Aph.) (10μg/ml for 20h) or 
treated with U0126 (20µM for 24h), 10058-F4 (100µM for 24h) and HLM006474 (40µM for 7 
days), and then RT-qPCR analyses of (a) stem cell-associated (nanog and oct-4) and (b) early 
differentiation (brachyury, alpha-fetoprotein or afp and nestin for mesoderm, endoderm and 
ectoderm, respectively) transcripts were performed. hPSCs differentiated using an embryoid 
body- (EB) based protocol, at days 4 (4d) and 7 (7d) of differentiation and NP were used as 
differentiated controls. rpl7 expression was used as normalizer. Graph shows mRNA fold 
induction relative to Control (Cont.) (asynchronous growing cells) or day 4 (4d) of the EB 
differentiation protocol. The mean + SEM from three independent experiments are shown. Und: 
undeterminated. (*) p<0.05, (**) p<0.01, (***) p<0.001 vs. Control. (c) hESCs (H9) and hiPSCs 
(FN2.1) grown and maintained in fully defined conditions (Vitronectin coated dishes and E8 
medium) were treated with Nocodazole (NOCO, 100ng/ml for 24h), GSK690693 (10µM for 
24h), U0126 (20µM for 24h), 10058-F4 (100µM for 24h), HLM006474 (40µM for 7 days), MG-
132 (MG132, 62.5nM for 24 h), CDK2 inhibitor II (CKD2i, 5µM for 24h) and CHIR99021 
(CHIR, 10µM for 24h) and then RT-qPCR analyses of stem cell-associated (nanog and oct-4) 
markers were performed. rpl7 expression was used as normalizer. Graph shows mean + SEM 
mRNA fold induction relative to Vehicle (DMSO treated) control cells (arbitrarily set as 1) of 













Changes in cyclins mRNA expression levels throughout hPSCs cell cycle progression after 
























Supplementary Figure 5. Changes in cyclins mRNA expression levels throughout hPSCs cell 
cycle progression after Aphidicolin block and release. H9 hESCs and FN2.1 hiPSCs grown in 
Vitronectin coated dishes with E8 medium were synchronized at G1/S boundary by Aphidicolin 
(Aph.) block (10μg/ml for 20h) and released to enter the cell cycle, and then cyclins A2, B1, D1, 
D2 and D3 mRNA expression levels were quantified by RT-qPCR in asynchronous or at 
different time points after Aphidicolin (Aph.) removal. rpl7 expression was used as normalizer. 
Graphs show mean + SEM mRNA fold induction relative to asynchronous control cells 
(arbitrarily set as 1) of three independent experiments. h: hours. (*) p<0.05 and (**) p<0.01 vs. 
Control (asynchronous cells). 
 














Supplementary Figure 6. Representative images of Western blot analyses. Representative 
images of Western blot analyses (whole membranes) of cyclins (D1, D2, E1, A and B1) 












(Asynchronous) or arrested in G1 with PD0332991 (PD) (1µΜ for 48h for HF, 5μM for 30h for 
hPSCs and 1μM for 24h for NP). Actin was used as loading control. Positive control: HeLa cells 
lysate provided by manufacturer. 
 
